Severe Gastritis after Administration of Nivolumab and Ipilimumab
Immune checkpoint inhibitors such as ipilimumab, a cytotoxic T-lymphocyte-associated antigen-4 inhibitor, have been widely used for advanced malignancies. As these inhibitors improve antitumor immunity via T-cell modulation, immune-mediated adverse events associated with T-cell activation, such as c...
Main Authors: | Yoshito Nishimura, Miho Yasuda, Kazuki Ocho, Masaya Iwamuro, Osamu Yamasaki, Takehiro Tanaka, Fumio Otsuka |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2018-08-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/491862 |
Similar Items
-
Combination of nivolumab and ipilimumab in the treatment of disseminated renal cell carcinoma. Realities and prospects
by: B. Ya. Alekseev, et al.
Published: (2020-11-01) -
Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials
by: Omid Kooshkaki, et al.
Published: (2020-06-01) -
Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report
by: Brendan John Guercio, et al.
Published: (2021-03-01) -
Infección por Helicobacter pylori en pacientes con mucosa sana y con gastritis erosiva Helicobacter pylori infection present in patients with a healthy mucosa and erosive gastritis
by: María Teresa Martínez Echavarría, et al.
Published: (2009-06-01) -
Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
by: Zhou S, et al.
Published: (2019-01-01)